Brief: Bioarctic Says Global License Agreement With Bristol Myers Squibb For Pyroglutamate-Amyloid-Beta Antibody Program Effective After Antitrust Clearance And Closing
20/02/2025 05:34
Feb 20 (Reuters) - BioArctic AB BIOAb.ST :
* BIOARCTIC'S GLOBAL LICENSE AGREEMENT WITH BRISTOL MYERS
SQUIBB
FOR PYROGLUTAMATE-AMYLOID-BETA ANTIBODY PROGRAM EFFECTIVE AFTER
ANTITRUST CLEARANCE AND CLOSING
* BIOARCTIC AB - TO RECEIVE $100 MILLION UPFRONT PAYMENT
* BIOARCTIC AB - AGREEMENT INCLUDES UP TO $1.25 BILLION IN
MILESTONES
* BIOARCTIC AB - RETAINS OPTION TO CO-COMMERCIALIZE IN
NORDIC
REGION
Source text: ID:nWkr95jbXk
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln